These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34699722)

  • 1. Fragment-Based Phenotypic Lead Discovery To Identify New Drug Seeds That Target Infectious Diseases.
    Ayotte Y; Bernet E; Bilodeau F; Cimino M; Gagnon D; Lebughe M; Mistretta M; Ogadinma P; Ouali SL; Sow AA; Chatel-Chaix L; Descoteaux A; Manina G; Richard D; Veyrier F; LaPlante SR
    ACS Chem Biol; 2021 Nov; 16(11):2158-2163. PubMed ID: 34699722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis.
    Ayotte Y; Bilodeau F; Descoteaux A; LaPlante SR
    ChemMedChem; 2018 Jul; 13(14):1377-1386. PubMed ID: 29722149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits.
    Blaazer AR; Orrling KM; Shanmugham A; Jansen C; Maes L; Edink E; Sterk GJ; Siderius M; England P; Bailey D; de Esch IJ; Leurs R
    J Biomol Screen; 2015 Jan; 20(1):131-40. PubMed ID: 25231971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
    Van Voorhis WC; Adams JH; Adelfio R; Ahyong V; Akabas MH; Alano P; Alday A; Alemán Resto Y; Alsibaee A; Alzualde A; Andrews KT; Avery SV; Avery VM; Ayong L; Baker M; Baker S; Ben Mamoun C; Bhatia S; Bickle Q; Bounaadja L; Bowling T; Bosch J; Boucher LE; Boyom FF; Brea J; Brennan M; Burton A; Caffrey CR; Camarda G; Carrasquilla M; Carter D; Belen Cassera M; Chih-Chien Cheng K; Chindaudomsate W; Chubb A; Colon BL; Colón-López DD; Corbett Y; Crowther GJ; Cowan N; D'Alessandro S; Le Dang N; Delves M; DeRisi JL; Du AY; Duffy S; Abd El-Salam El-Sayed S; Ferdig MT; Fernández Robledo JA; Fidock DA; Florent I; Fokou PV; Galstian A; Gamo FJ; Gokool S; Gold B; Golub T; Goldgof GM; Guha R; Guiguemde WA; Gural N; Guy RK; Hansen MA; Hanson KK; Hemphill A; Hooft van Huijsduijnen R; Horii T; Horrocks P; Hughes TB; Huston C; Igarashi I; Ingram-Sieber K; Itoe MA; Jadhav A; Naranuntarat Jensen A; Jensen LT; Jiang RH; Kaiser A; Keiser J; Ketas T; Kicka S; Kim S; Kirk K; Kumar VP; Kyle DE; Lafuente MJ; Landfear S; Lee N; Lee S; Lehane AM; Li F; Little D; Liu L; Llinás M; Loza MI; Lubar A; Lucantoni L; Lucet I; Maes L; Mancama D; Mansour NR; March S; McGowan S; Medina Vera I; Meister S; Mercer L; Mestres J; Mfopa AN; Misra RN; Moon S; Moore JP; Morais Rodrigues da Costa F; Müller J; Muriana A; Nakazawa Hewitt S; Nare B; Nathan C; Narraidoo N; Nawaratna S; Ojo KK; Ortiz D; Panic G; Papadatos G; Parapini S; Patra K; Pham N; Prats S; Plouffe DM; Poulsen SA; Pradhan A; Quevedo C; Quinn RJ; Rice CA; Abdo Rizk M; Ruecker A; St Onge R; Salgado Ferreira R; Samra J; Robinett NG; Schlecht U; Schmitt M; Silva Villela F; Silvestrini F; Sinden R; Smith DA; Soldati T; Spitzmüller A; Stamm SM; Sullivan DJ; Sullivan W; Suresh S; Suzuki BM; Suzuki Y; Swamidass SJ; Taramelli D; Tchokouaha LR; Theron A; Thomas D; Tonissen KF; Townson S; Tripathi AK; Trofimov V; Udenze KO; Ullah I; Vallieres C; Vigil E; Vinetz JM; Voong Vinh P; Vu H; Watanabe NA; Weatherby K; White PM; Wilks AF; Winzeler EA; Wojcik E; Wree M; Wu W; Yokoyama N; Zollo PH; Abla N; Blasco B; Burrows J; Laleu B; Leroy D; Spangenberg T; Wells T; Willis PA
    PLoS Pathog; 2016 Jul; 12(7):e1005763. PubMed ID: 27467575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The re-emergence of natural products for drug discovery in the genomics era.
    Harvey AL; Edrada-Ebel R; Quinn RJ
    Nat Rev Drug Discov; 2015 Feb; 14(2):111-29. PubMed ID: 25614221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-infectives: can cellular screening deliver?
    Keller TH; Shi PY; Wang QY
    Curr Opin Chem Biol; 2011 Aug; 15(4):529-33. PubMed ID: 21723774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation antimicrobials: from chemical biology to first-in-class drugs.
    Ang ML; Murima P; Pethe K
    Arch Pharm Res; 2015 Sep; 38(9):1702-17. PubMed ID: 26259630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial drug discovery.
    Fairlamb A; Cole S
    Future Microbiol; 2011 Jun; 6(6):601-2. PubMed ID: 21707305
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel approach of fragment-based lead discovery applied to renin inhibitors.
    Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
    Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery.
    Okombo J; Chibale K
    Acc Chem Res; 2017 Jul; 50(7):1606-1616. PubMed ID: 28636311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway.
    Fletcher S; Avery VM
    Malar J; 2014 Aug; 13():343. PubMed ID: 25174342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing diversity-oriented synthesis in antimicrobial drug discovery.
    Comer E; Duvall JR; duPont Lee M
    Future Med Chem; 2014; 6(17):1927-42. PubMed ID: 25495985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using computational techniques in fragment-based drug discovery.
    Desjarlais RL
    Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural biology in fragment-based drug design.
    Murray CW; Blundell TL
    Curr Opin Struct Biol; 2010 Aug; 20(4):497-507. PubMed ID: 20471246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic Screening of Small Molecules with Antimalarial Activity for Three Different Parasitic Life Stages.
    Kato N; March S; Bhatia SN; Marti M
    Methods Mol Biol; 2018; 1787():41-52. PubMed ID: 29736708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immucillins in Infectious Diseases.
    Evans GB; Tyler PC; Schramm VL
    ACS Infect Dis; 2018 Feb; 4(2):107-117. PubMed ID: 29151351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial phenotypic screen uncovers unrecognized family of extended thiourea inhibitors with copper-dependent anti-staphylococcal activity.
    Dalecki AG; Malalasekera AP; Schaaf K; Kutsch O; Bossmann SH; Wolschendorf F
    Metallomics; 2016 Apr; 8(4):412-21. PubMed ID: 26935206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
    Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
    Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment screening: an introduction.
    Leach AR; Hann MM; Burrows JN; Griffen EJ
    Mol Biosyst; 2006 Sep; 2(9):430-46. PubMed ID: 17153140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.